{"nctId":"NCT01360762","briefTitle":"Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study","startDateStruct":{"date":"2011-11"},"conditions":["Visceral Leishmaniosis","HIV-infection/Aids"],"count":74,"armGroups":[{"label":"Pentamidine Secondary Prophylaxis (PSP)","type":"EXPERIMENTAL","interventionNames":["Drug: Pentamidine"]}],"interventions":[{"name":"Pentamidine","otherNames":["PENTACARINAT 300 mg, by Sanofi-Aventis"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients diagnosed with Visceral Leishmaniosis (VL) during the recruitment period that are EITHER treated for VL relapse and have a documented negative test of cure (TOC), OR are treated for primary VL and have a documented CD4 \\<200 or WHO stage 4 disease during the recruitment period and have a documented negative TOC\n* Patients treated for VL in the past with documented CD4 \\<200 or WHO stage 4 disease during the recruitment period AND documented negative TOC after the latest VL treatment and currently asymptomatic OR currently negative diagnostic test (microscopy)\n* Patients agreeing to start or continue antiretroviral treatment (first or second line)\n* Patients willing to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with known hypersensitivity to pentamidine\n* Patients with known renal failure\n* Patients with diabetes mellitus (type I or II)\n* Patients unlikely to attend follow-up visits/comply with study requirements\n* Pregnant and lactating women\n* Any other condition that could increase the risk of toxicity of pentamidine to such an extent outweighing the expected benefit (eg severe cardiac dysfunction).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Probability of Relapse-free Survival","description":"Probability of relapse-free survival up to one year after the start of the intervention (PSP) (at month 6 and month 12)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"Number of patients with SAEs which are possibly, probably or definitely drug-related following clinician's assessment or that lead to permanent drug discontinuations during the first year of pentamidine administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"During the first year of pentamidine administration for prophylaxis: participants with any drug-related non-serious adverse events (with drug-related defined as possibly, probably or definitely related to primary therapy following physicians assessment) as well as any serious adverse events (drug-related or not)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Discontinuations and Interruptions","description":"Number of treatment discontinuations and interruptions/missed doses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Required Additional Interventions","description":"The number of required additional clinical interventions/therapeutic procedures","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":74},"commonTop":["Pneumonia","Visceral leishmaniasis","Malaria","Gastroenteritis","Nasal congestion"]}}}